title: Intraoperative anaphylaxis to gelatin in topical hemostatic agents during anterior spinal fusion: a case report.
abstract: BACKGROUND
  The use of topical hemostatic agents is widespread and has been shown to reduce bleeding during a wide variety of surgical procedures. Nonetheless, as biologically active agents, there is potential for allergic reactions to these products.
  
  
  OBJECTIVE
  This is a report of intraoperative anaphylaxis to gelatin associated with the use of two topical hemostatic agents.
  
  
  METHODS
  Case report. There is no outside funding or potential conflict of interest.
  
  
  METHODS
  A patient with anaphylaxis during anterior spinal fusion.
  
  
  METHODS
  Laboratory assays for tryptase, gelatin-specific immunoglobulin E (IgE), and total IgE.
  
  
  METHODS
  A 14-year-old male with myelomeningocele and scoliosis was treated with anterior spinal fusion from T12 to L3. Gelfoam sponges were applied during the preparation of the disc spaces. Approximately 1 hour later, Floseal hemostatic matrix was applied to a briskly bleeding screw hole in the L3 vertebral body, and the patient experienced an abrupt onset of hypotension and ventilatory difficulty. Epinephrine, dexamethasone, and blood products were administered for hemodynamic support while the surgical site was closed. Removal of the drapes revealed a widespread erythematous rash, and the patient was then transferred to the intensive care unit. When stable 3 days later, he returned to the operating room for completion of the spinal fusion.
  
  
  RESULTS
  Postoperative laboratory assays were sent that revealed elevated levels of tryptase, total IgE, porcine, and bovine gelatin-specific IgE. The patient was counseled to avoid gelatin-containing products. At 6-month follow-up, his instrumented spine was radiographically fused and he reported no further allergic issues.
  
  
  CONCLUSIONS
  Anaphylaxis may occur because of animal gelatin components of topical hemostatic agents. Previous reports have focused on the thrombin components. Care should be taken in the administration of these products, particularly in the atopic individual.
authors.affiliation: Department of Orthopaedic Surgery, Children's Hospital Boston, 300 Longwood Ave., Boston, MA 02115, USA. Hillard.Spencer@childrens.harvard.edu
authors.forename: Hillard T
authors.initials: HT
authors.lastname: Spencer
authors.forename: Joyce T
authors.initials: JT
authors.lastname: Hsu
authors.forename: Douglas R
authors.initials: DR
authors.lastname: McDonald
authors.forename: Lawrence I
authors.initials: LI
authors.lastname: Karlin
mesh_terms: D000293:Adolescent; D000707:Anaphylaxis / Q000209:etiology* / Q000628:therapy; D016063:Blood Loss, Surgical / Q000517:prevention & control; D005780:Gelatin / Q000009:adverse effects*; D005781:Gelatin Sponge, Absorbable / Q000009:adverse effects; D006490:Hemostatics / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008591:Meningomyelocele / Q000601:surgery*; D012600:Scoliosis / Q000601:surgery*; D013123:Spinal Fusion
chemical_list: C411004:FloSeal Matrix; D006490:Hemostatics; D005780:Gelatin